Smith & Nephew books Q1 sales slightly better than projections

The British medtech firm and Coloplast rival, Smith & Nephew, goes up on the London stock exchange after publicizing its Q1 figures.

Smith & Nephew has a good day on the stock exchange in London after delivering better-than-expected sales figures from Q1

Following Smith & Nephew’s first quarterly report from 2022, the company’s stock price increased 2.4 percent to GBP 12.99 on the London stock exchange.

The British medtech firm, a competitor of Coloplast within wound care, booked sales of USD 1.31bn in Q1, which ended on April 2. Analysts’ estimates, according to Bloomberg News, put the company at USD 1.27bn prior to the report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs